Lorlatinib-induced visual and auditory hallucinations: A case report

Jun Hakamata; Hideo Nakada; Hiroshi Muramatsu; Keita Masuzawa; Hideki Terai; Shinnosuke Ikemura; Koichi Fukunaga; Tohru Aomori

doi:10.1002/ccr3.4040

Lorlatinib-induced visual and auditory hallucinations: A case report

Clin Case Rep. 2021 Apr 7;9(8):10.1002/ccr3.4040. doi: 10.1002/ccr3.4040. eCollection 2021 Aug.

Authors

Jun Hakamata¹, Hideo Nakada², Hiroshi Muramatsu¹, Keita Masuzawa^{3

4}, Hideki Terai⁵, Shinnosuke Ikemura^{3

6}, Koichi Fukunaga³, Tohru Aomori^{1

2}

Affiliations

¹ Department of Pharmacy Keio University Hospital Tokyo Japan.
² Division of Hospital Pharmacy Science Faculty of Pharmacy Keio University Tokyo Japan.
³ Division of Pulmonary Medicine Department of Medicine Keio University School of Medicine Tokyo Japan.
⁴ Division of Pulmonary Medicine Department of Medicine Kitasato University Kitasato Institute Hospital Tokyo Japan.
⁵ Keio University Hospital Clinical and Translational Research Center Tokyo Japan.
⁶ Department of Cancer center Keio University Hospital Tokyo Japan.

Abstract

Lorlatinib can cause visual and auditory hallucinations. And, it is necessary to keep in mind that hallucinations can persist even after discontinuation in patients who develop hallucinations while receiving lorlatinib.

Keywords: Japanese patient; hallucinations; lorlatinib; nonsmall‐cell lung cancer.

Publication types

Case Reports